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Introduction: Acromegaly is chronic progressive disease with multisystem 
involvement characterised by an excess secretion of growth hormone and 
increased circulating insulin like growth factor 1 concentration.
Aims and Objectives: To assess surgical outcome of acromegaly patients at 
tertiary care institute using SF 36 quality of life questionnaire. SF-36 scores 
comprise 3 components: the physical component summary (PCS), the mental 
component summary (MCS) and role-social component summary (RCS).
30 acromegaly patients admitted in Guwahati medical college were 
enrolled in study and followed up post operatively for surgical remission. 
All participants completed the SF-36 preoperatively, 1 year and 2 years 
postoperatively.
Material and Method: Out of 30 patients 6 patients had surgical remission 
post operatively on the basis of postoperative glucose suppressed GH Level 
done after 12 weeks. Preoperatively subscale scores (physical functioning, 
role physical, general health) which were below the set standards for the 
normal population show significant postoperative improvements along with 
mental health (MH) scores. Similarly, PCS, MCS and RCS scores changed 
significantly after surgery. We also compared the QOL of 6 patients whose 
peak GH level was < 0.4 µg/L during postoperative oral glucose tolerance 
testing with those patients whose nadir GH level was ≥ 0.4 µg/L. There 
was significant difference between partial and complete remission group in 
subscale score role physical, social function and mental health. Similarly, 
PCS and RCS score significantly different in partial and complete remission 
group than MCS score.
Conclusions: QOL is considerably reduced in patients with acromegaly 
compared to general population which improves significantly after surgical 
treatment. Patients achieving the new remission criteria had significant 






Acromegaly is a chronic illness characterised by chang-
es in appearance, skeletal deformities and various met-
abolic disorders. In 95% of cases, acromegaly is caused 
by excessive secretion of the growth hormone (GH) by 
a hormonally active adenoma of the anterior lobe of the 
pituitary gland (GHoma) which in turn leads to excessive 
secretion of insulin-like growth factor-1 (IGF-1). Exces-
sive secretion of IGF-1 results in bone and soft tissue 
proliferation in the distal extremities, the jaw, tongue, lips, 
nose and the frontal eminence. Disease control by vari-
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ous means can improve metabolic function, improve life 
expectancy and reduce morbidity [1-3]. Metabolic abnor-
malities associated with acromegaly lead to cardiac hyper-
trophy, heart failure and increased incidence of ischemic 
heart disease which is the leading cause of death in pa-
tients with acromegaly [4-5]. The introduction advanced 
surgical techniques have significantly improved the cure 
rate of acromegaly patients [6-8]. Remission of acromegaly 
is usually defined on the basis of 3 month post-operative 
suppressed GH< 1 ug/l, however according to a new con-
sensus guideline based on GH suppression to < 0.4 µg/
L and age and sex adjusted IGF 1 level is recommended 
[9]. We do not know the effect of surgical remission on the 
post-operative QOL in patients with acromegaly and also 
of new consensus criteria. So, we conducted this study to 
assess the effect of surgical treatment on quality of life 
using SF36 questionnaire in a prospective cohort of acro-
megaly patients. We also evaluated the quality of life in 
patients who have achieved remission according to new 
consensus criteria.
2. Material Methods
30 newly diagnosed acromegaly patients (14 men and 
16 women) based on clinical, biochemical and radiolog-
ical features with an average age of 44.5 years (range 
21-67) were included in study. The diagnosis of acro-
megaly was confirmed with post oral glucose tolerance 
test (OGTT) GH >1.0 μg/L, and IGF-I level was above 
the upper normal range for age and sex. Patients were 
treated using transsphenoidal surgery performed by a 
senior neurosurgeon during period of 2015-2019. IGF-1 
normalization was achieved in 6 out of 30 patients (20%) 
according to new consensus criteria (peak GH level dur-
ing the OGTT of < 0.4 µg/L). All participants underwent 
an OGTT 3 months post-surgery and based on that peak 
GH level were divided into old consensus criteria (nadir 
GH level during the OGTT of < 1 µg/L or >1ug/L): the 
complete remission group or the not in remission group. 
Complete remission group was further divided according 
to a new consensus guideline into: the complete remission 
group and the partial remission group (postoperative nadir 
GH level during the OGTT of < 0.4 µg/L or ≥ 0.4 µg/L). 
We compared the clinical and biochemical characteristics, 
and postoperative SF-36 scores between the two groups. 
We also did pre- and post-surgical hormonal profile and 
follow-up patients 3 monthly. 
3. Survey Methods
We conducted thorough Clinical and biochemical ex-
aminations pre- and 3-month post- surgery. The validity 
and reliability of SF-36 have been already established 
in Indian population and has been used to assess health 
outcomes in several diseased population [10,11]. All 30 pa-
tients completed SF 36 quality of life questionnaire at the 
assessment. The quality-of-life questionnaire evaluates 12 
items regarding a patient’s general well-being, each item 
has multiple questions under it and all questions have 5 
possible answers. All questions are scored on a scale of 
1–5. The items are scored in various scales: physical func-
tioning, daily activities, symptoms, social, psychological, 
general health perception, sleep, sexual health, pain, en-
ergy, body image and cognition. Higher the scores poor is 
the quality of life. We compared the pre- and post- opera-
tive quality of life questionnaire scores. All patients com-
pleted preoperative questionnaire. In this questionnaire, 
responses to questions around physical symptoms — My 
body has enlarged/ grown enormously — could be given 
as “not important”, “slightly important”, “important”,” 
fairly important” or “very important”. We also assessed 
the severity of obstructive sleep apnoea with the help of 
polysomnography which is shown by the apnoea hypo-
pnea index (AHI).
4. Statistical Analysis
Subjects were divided based on remission criteria. 
Spearman correlation coefficients were calculated be-
tween the change in IGF-I levels and SF 36 scores. 
Non-parametric tests (Mann-Whitney U and Kruskal-Wal-
lis one-way ANOVA) were performed to test the statistical 
significance of differences between different groups. All 
statistical analyses were performed with SPSS software 
and a p<0.05 was considered statistically significant. In-
formed consent was obtained from all the individual par-
ticipating in study. 
5. Results
Table 1 shows the baseline characteristics of individu-
als. A total of 14 males and 16 female individuals Patient 
with mean age of 44.5 years (21-67) and mean duration 
of symptoms7.6 years (4 years-15 years) were included. 
Dyslipidaemia was the most common co-morbidity (80%), 
followed by hypertension (73%) and diabetes (60%). 
Coronary artery disease was present in 8 (26%) patients 
at baseline with none of them having history of cerebro-
vascular accident or malignancy. Acral enlargement was 
the most common symptom (73%) followed by arthralgia 
and fatigue (66%) (Table 2). Hyperprolactinemia (53%) 
was the most common hormonal abnormality followed 
by low cortisol (40%), hypothyroidism(30%), hypog-
onadism (23%) and diabetes insipidus (10%) (Table 3). 
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Pituitary macroadenoma was found in (83%), followed by 
microadenoma(10%) and empty Sella (6.6%). On immu-
nohistochemistry 24 patients had somatotroph adenoma, 
4 patients had mamo-somatotroph adenoma and 2 patients 
had pleurihormonal adenoma. All patients were treated 
with surgery for IGF-1 normalization. Preoperative mean 
stimulated GH level was 66.4±55.4 ng/ml (1.5-185) and 
postoperative stimulated GH was 6±4.9 ng/ml (0.1-16) 
which was significant (p-0.003). The preoperative IGF-
1 levels ranged from 344.0 µg/L to 1400.0 µg/L (mean: 
797.3 ± 275.1 µg/L). There was a significant reduction 
in postoperative serum IGF-1 levels (388 ± 200 µg/L, p 
-0.003). No significant change in proportion of patients 
with hypertension, diabetes mellitus, or hyperlipidaemia, 
AHI. Fewer patients required hormonal replacement post 
operatively at 12month (Hyperprolactinemia-8, Hypothy-
roidism-4, low cortisol-6, hypogonadism-5, diabetes insip-
idus-1). Figure 1 shows Preoperative and postoperative (12 
month and 24 month) subscale scores. Preoperative phys-
ical functioning (PF), role physical (RP), general health 
(GH) was below the national standard value as indicated 
by the boxed value. Significant postoperative improve-
ments were observed for the physical functioning (PF) 
(53±10.4 vs 60±8.7 vs 63.3±6.7, p<0.0001), role physical 
(RP) (50.1±8.7 vs 60±9.9 vs 60.8±13.3, p<0.0001), gener-
al health (GH) (47.5±8.3 vs 63.6±8.1 vs 62.1±8.8, p,0.001) 
and mental health (MH) (58±7.8 vs 64.8±6.8 vs 70±6, 
p<0.0001) scores but not in bodily pain (BP) (62.8±9.1 vs 
63.5±9.2 vs 63.6±9.1, p-0.934 ), vitality (VT)(65.1±7.2 vs 
65.3±7.1 vs 65.6±7.6, p-0.965), social functioning (SF) 
(64.6±7.7 vs 64.8±7.7 vs 65.8±7, p-0.969), role emotional 
(RE) (63.1±8 vs 63.3±7.6 vs 63.5±7.6, p-0.986). Figure 
2 shows the preoperative and postoperative results of 
PCS, MCS, and RCS score. The baseline score was close 
to the national standard. The PCS, MCS and RCS scores 
did change significantly after surgery. Figure 3 shows 
pre-operative and post-operative subscale score in patient 
group. There was significant difference in subscale score 
between partial and complete remission group in role 
physical (RP) (57.6±12.7 vs 71.4±9.8, p-0.014), social 
function (SF) (63.4±7.8 vs 70.7±6, p-0.05) and mental 
health (MH) (68.4±5.7 vs 75±4, p-0.009). Similarly, PCS 
(64.2±4.4 vs 67.5±4.6, p<0.012) and RCS (60.9±5.4 vs 
69.2±5.4, p<0.0001) score significantly different in partial 
and complete remission group than MCS score (62.7±5.3 
vs 67.1±5, p-0.064).
Table 1. Table showing baseline characteristics with radi-



















Table 2. Showing predominant symptoms in individual 
patients
Symptoms(N-30) Number of patients
Acral enlargement 22(73%)





















Diabetes Insipidus 3 (10%) 1(3%)






Diabetes Mellitus 18(60%) 14(46%) -
Hypertension 22(73%) 20(66%) -














CAD 8(26%) 8(26%) -
CVA 0 - -
Cancer 0 - -
GH (Glucose stimulated) 66.4±55.4 ng/ml 6±4.9 ng/ml 0.003
IGF 1 797.3 ± 275.1 µg/l 388 ± 200 µg/l 0.003




Journal of Endocrinology Research | Volume 03 | Issue 02 | July 2021
Distributed under creative commons license 4.0
Figure 1. Showing preoperative and postoperative sub-
scale score
Figure 2. Showing preoperative and postoperative com-
ponent score
Figure 3. Showing subscale score in complete and partial 
remission group
Figure 4. Showing component score in partial and com-
plete remission group
6. Discussion
Acromegaly is associated with various disabilities with 
poor quality of life. There are very few prospective studies 
reporting postoperative changes in QOL among patients 
treated by surgery alone. 
Our study showed preoperative SF-36 scores were 
lower in acromegaly patients than that of the general pop-
ulation in subscales, including physical functioning, role 
physical, general health which indicate that acromegaly 
significantly affects patient’s physical condition, self-per-
ception as well as participation. We found that postop-
erative there was significant improvement in physical 
component, mental component and role social component 
of SF36 QOL questionnaire. Sardella et al. [12] on the 
other hand found that surgical cure resulted in improve-
ments in the mental components as compared to physical 
or role-social components of SF 36 QOL questionnaire. 
Yoshida et al. [13] in acromegaly patients reported higher 
psychological scores in patients with surgically achieved 
disease control. Biermasz et al. [14] found better physical 
function in surgically cured acromegaly patients. 
Shingo Fujio [15] using SF-36 questionnaire found MCS 
score improved significantly postoperatively while there 
was no significant difference in PCS, RCS and MCS 
scores between complete and partial remission groups. 
We, on the contrary found that there was significant post-
operative improvement in PCS, RCS and MCS scores but 
MCS score did not change significantly between complete 
and partial remission group.
All of our patients achieved IGF-1 normalization by 
surgery alone, and fewer number of patients required post-
operative hormone replacement therapy. Several comor-
bidities, such as joint pain due to severe arthritis, myopa-
thy and hypertension, impairs postoperative improvement 
DOI: https://doi.org/10.30564/jer.v3i2.3531
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in physical and emotional subscale score in some patients 
with acromegaly even after achievement of postoperative 
cure. 
Gilbert et al. [16] in his study showed improvements in 
health perception and fatigue during medical treatment 
among newly-diagnosed with acromegaly. In addition, 
Sardella et al. [12] in Acromegaly patients observed im-
provements in psychological and appearance domains 
after a 6-month course of a somatostatin analog. Matta et 
al. [17] reported higher AcroQoL psychological subscale 
scores in controlled acromegaly patients compared to pa-
tients with uncontrolled disease.
There was significant difference in subscale score be-
tween partial and complete remission group in role phys-
ical (RP), social function (SF) and mental health (MH). 
In a similar study Renata Aparecida Elias Dantas [18] in 
acromegalic patients found the scores obtained on SF-36 
domains were higher in patients with controlled disease 
and statistical differences were found in the domains Role 
Physical, Pain, Vitality, Role Emotional.
Kauppinen Mäkelin et al. [19] in his study reported that 
a post OGTT nadir GH level in the 0.3– 1.0 µg/L range 
could achieve the best QOL but not < 0.3 µg/L. Post 
OGTT nadir GH level <0.3 µg/L might have GH deficien-
cy and adversely affect QOL. None of our patients devel-
oped post OGTT low GH suggestive of GH deficiency 
although we could not perform GH secretory function in 
our patient group.
Significant number of patients present with diabetes 
mellitus, hypertension and hyperlipidaemia pre-operative-
ly which decreased post-surgery. However, the dose of 
antidiabetic and antihypertensive medication decreased in 
some cases but antihypertensives could not be withdrawn 
which could be due to irreversible remodelling of vascular 
system.
Small sample size has limited the generalization of our 
study. We need large studies to evaluate the effects of the sur-
gical remission on the QOL of patients with acromegaly.
Some of the limitations of our study are, we have used 
SF-36 questionnaire which may be less sensitive when 
compared with disease-specific questionnaires, such as 
the AcroQoL questionnaire. OGTT will change depending 
upon the time of its performance [20]. We have performed 
OGTT at 3 months interval which could be different at 1 
year when we administered SF36 questionnaire. We have 
evaluated SF 36 scores at baseline, 1 year and 2 years 
post-surgery but patient’s score can change at any time. 
Therefore, long term studies with extended follow-up is 
needed to confirm the long-term effects of surgery. Final-
ly, further studies are needed to gather information regard-
ing the impact of GH deficiency on postoperative QOL. 
7. Conclusions
Acromegaly is debilitating illness with multisystem 
involvement and poor QOL. Our study showed that ac-
romegaly leads to low preoperative SF-36 QOL scores 
compared to the general population. Surgical remission 
leads to an improvement in the mental, physical and so-
cial domain of SF 36 QOL scores. There were significant 
differences in physical and social scores of QOL between 
complete and partial remission group. Although, small 
sample size has limited the generalisation of the finding of 
our study, there are few prospective studies reporting post-
operative changes in QOL among patients cured solely 
by surgery. We need further large-scale long-term studies 
with extended follow-up to evaluate the effects of surgery 
as well as newer stricter remission criteria on QOL.
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